JYNT
BEARISH
$8.73
Live
The Joint Corp. · NASDAQ
Target $10.0
(+14.5%)
$7.5
52W Range
$13.47
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 13, 2026
Market cap
$125.04M
P/E
N/A
ROE
-1.5%
Profit margin
5.3%
Debt/Equity
0.13
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
The Joint Corp. (JYNT) exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 2/9, indicating poor financial health and deteriorating operational efficiency. Despite a low debt-to-equity ratio, the company suffers from negative ROE (-1.50%) and a staggering 5-year price decline of 83.5%. Valuation is prohibitively high with a Price/Book ratio of 8.20 and a Forward P/E of 38.80, which is not supported by a stagnant revenue growth rate of 3.10%. The massive reported earnings growth is likely a mathematical anomaly resulting from a low base effect rather than sustainable organic growth.
Key Strengths
Very low Debt/Equity ratio (0.13)
Healthy Current Ratio (1.59)
Strong Gross Margins (79.55%)
Positive Profit Margin (5.30%)
Low overall leverage compared to healthcare sector average
Key Risks
Critical Piotroski F-Score (2/9) signaling fundamental decay
Severe long-term value destruction (-83.5% 5Y return)
Extreme overvaluation relative to book value (P/B 8.20)
Stagnant revenue growth (3.10% YoY)
Negative Return on Equity (ROE) and Return on Assets (ROA)
AI Fair Value Estimate
Based on comprehensive analysis
$6.5
-25.5% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
19
Weak
20
30
10
35
0
AI Verdict
Avoid
Key drivers: Poor Piotroski score, Negative ROE, High P/B ratio, Long-term bearish price trend
Confidence
90%
Value
20/100
Graham Number unavailable; valuation is disconnected from fundamental book value.
Positives
- P/S ratio is moderate at 2.28
Watchpoints
- P/B of 8.20 is excessive for negative ROE
- Forward P/E of 38.80 is high for 3% revenue growth
Future
30/100
Growth rates do not justify the current valuation premium.
Positives
- Recent quarterly EPS beat in March 2026
Watchpoints
- Revenue growth is nearly flat (3.10%)
- Earnings volatility is extreme
Past
10/100
Historical trend is overwhelmingly bearish.
Positives
- Short-term 6-month recovery (+8.3%)
Watchpoints
- Catastrophic 5-year performance (-83.5%)
- Consistent failure to maintain long-term price levels
Health
35/100
Balance sheet is clean (low debt), but operational health is failing.
Positives
- Low Debt/Equity (0.13)
- Current Ratio > 1.5
Watchpoints
- Piotroski F-Score of 2/9 is a major red flag
- Negative ROA and ROE
Dividend
0/100
Non-dividend paying growth/recovery stock.
Positives
No standout positives identified.
Watchpoints
- No dividend payments
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$8.73
Analyst Target
$10.0
Upside/Downside
+14.5%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for JYNT and closest competitors.
Updated 2026-04-10
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
JYNT
The Joint Corp.
Primary
|
-83.5% | -44.4% | -12.2% | +8.3% | +2.6% | +1.5% |
|
HYPR
Hyperfine, Inc.
Peer
|
-88.1% | -17.1% | +81.4% | -30.9% | +2.5% | +7.1% |
|
IPHA
Innate Pharma S.A.
Peer
|
-67.1% | -58.3% | -22.5% | -30.5% | -9.0% | +2.9% |
|
FONR
FONAR Corporation
Peer
|
+3.3% | +15.4% | +48.2% | +20.1% | +0.7% | +0.1% |
|
DH
Definitive Healthcare Corp.
Peer
|
-97.5% | -89.8% | -57.4% | -66.5% | -13.7% | -13.0% |
JYN
The Joint Corp.
Primary
5Y
-83.5%
3Y
-44.4%
1Y
-12.2%
6M
+8.3%
1M
+2.6%
1W
+1.5%
HYP
Hyperfine, Inc.
Peer
5Y
-88.1%
3Y
-17.1%
1Y
+81.4%
6M
-30.9%
1M
+2.5%
1W
+7.1%
IPH
Innate Pharma S.A.
Peer
5Y
-67.1%
3Y
-58.3%
1Y
-22.5%
6M
-30.5%
1M
-9.0%
1W
+2.9%
FON
FONAR Corporation
Peer
5Y
+3.3%
3Y
+15.4%
1Y
+48.2%
6M
+20.1%
1M
+0.7%
1W
+0.1%
DH
Definitive Healthcare Corp.
Peer
5Y
-97.5%
3Y
-89.8%
1Y
-57.4%
6M
-66.5%
1M
-13.7%
1W
-13.0%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
38.8
PEG Ratio
N/A
P/B Ratio
8.2
P/S Ratio
2.28
EV/Revenue
1.85
EV/EBITDA
137.61
Market Cap
$125.04M
Profitability
Profit margins and return metrics
Profit Margin
5.3%
Operating Margin
4.25%
Gross Margin
79.55%
ROE
-1.5%
ROA
-0.78%
Growth
Revenue and earnings growth rates
Revenue Growth
+3.1%
Earnings Growth
+6276.7%
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
+5510.5%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.13
Low debt
Current Ratio
1.59
Good
Quick Ratio
0.81
Poor
Cash/Share
$1.67
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.0B
Gross Margin
81.4%
Op. Margin
4.9%
Net Margin
6.5%
Total Assets
$0.1B
Liabilities
$0.0B
Equity
$0.0B
Debt/Equity
3.05x
Operating CF
$0.0B
CapEx
$-0.0B
Free Cash Flow
$0.0B
FCF Yield
88%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-07
$N/A
2026-03-12
$0.07
+55.6% surprise
2025-11-06
$0.13
2025-08-07
$-0.06
-242.9% surprise
Healthcare Sector Comparison
Comparing JYNT against 291 companies in the Healthcare sector
(20 bullish, 99 neutral, 172 bearish)
Return on Equity (ROE)
-1.5%
This Stock
vs
-49.88%
Sector Avg
-97.0%
(Below Avg)
Profit Margin
5.3%
This Stock
vs
-9.43%
Sector Avg
-156.1%
(Weaker)
Debt to Equity
0.13
This Stock
vs
3.74
Sector Avg
-96.4%
(Less Debt)
Revenue Growth
3.1%
This Stock
vs
80.78%
Sector Avg
-96.2%
(Slower)
Current Ratio
1.59
This Stock
vs
3.72
Sector Avg
-57.3%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
JYNT
The Joint Corp.
|
BEARISH | $125.04M | - | -1.5% | 5.3% | $8.73 | |
|
HYPR
Hyperfine, Inc.
|
NEUTRAL | $119.21M | - | -79.0% | -262.3% | $1.21 | Compare |
|
IPHA
Innate Pharma S.A.
|
BEARISH | $132.24M | - | -% | -% | $1.41 | Compare |
|
FONR
FONAR Corporation
|
NEUTRAL | $117.26M | 16.18 | 6.0% | 7.1% | $18.61 | Compare |
|
DH
Definitive Healthcare Corp.
|
NEUTRAL | $111.79M | - | -40.4% | -57.5% | $1.07 | Compare |
JYNT
The Joint Corp.
BEARISH
Mkt Cap
$125M
P/E
-
ROE
-1.5%
Price
$8.73
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-09 | BOWMAN SCOTT JUSTIN | Chief Financial Officer | Stock Award | 28,301 | - |
| 2026-03-09 | RAZDAN SANJIV KUMAR | Chief Executive Officer | Stock Award | 73,484 | - |
| 2026-02-12 | JOBSON CHARLES E | Beneficial Owner of more than 10% of a Class of Security | Purchase | 15,397 | $130,874 |
| 2026-02-11 | JOBSON CHARLES E | Beneficial Owner of more than 10% of a Class of Security | Purchase | 448 | $3,898 |
| 2026-01-26 | JOBSON CHARLES E | Beneficial Owner of more than 10% of a Class of Security | Purchase | 17,478 | $174,780 |
| 2026-01-06 | JOBSON CHARLES E | Beneficial Owner of more than 10% of a Class of Security | Purchase | 5,240 | $46,584 |
| 2026-01-02 | JOBSON CHARLES E | Beneficial Owner of more than 10% of a Class of Security | Purchase | 1,404 | $12,215 |
| 2025-12-05 | JOBSON CHARLES E | Beneficial Owner of more than 10% of a Class of Security | Purchase | 10,000 | $84,100 |
| 2025-12-01 | JOBSON CHARLES E | Beneficial Owner of more than 10% of a Class of Security | Purchase | 13,000 | $109,330 |
| 2025-11-25 | JOBSON CHARLES E | Beneficial Owner of more than 10% of a Class of Security | Purchase | 16,761 | $141,668 |
BOWMAN SCOTT JUSTIN
Chief Financial Officer
2026-03-09
28,301 shares
RAZDAN SANJIV KUMAR
Chief Executive Officer
2026-03-09
73,484 shares
JOBSON CHARLES E
Beneficial Owner of more than 10% of a Class of Security
2026-02-12
15,397 shares
·
$130,874
JOBSON CHARLES E
Beneficial Owner of more than 10% of a Class of Security
2026-02-11
448 shares
·
$3,898
JOBSON CHARLES E
Beneficial Owner of more than 10% of a Class of Security
2026-01-26
17,478 shares
·
$174,780
JOBSON CHARLES E
Beneficial Owner of more than 10% of a Class of Security
2026-01-06
5,240 shares
·
$46,584
JOBSON CHARLES E
Beneficial Owner of more than 10% of a Class of Security
2026-01-02
1,404 shares
·
$12,215
JOBSON CHARLES E
Beneficial Owner of more than 10% of a Class of Security
2025-12-05
10,000 shares
·
$84,100
JOBSON CHARLES E
Beneficial Owner of more than 10% of a Class of Security
2025-12-01
13,000 shares
·
$109,330
JOBSON CHARLES E
Beneficial Owner of more than 10% of a Class of Security
2025-11-25
16,761 shares
·
$141,668
Insider transactions can signal confidence or concerns about company prospects
Past News Coverage
Recent headlines mentioning JYNT from our newsroom.
Newest → oldest
No matching news yet.